MedTrace Logo

Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

NCT07170761 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2026-03-05

No results posted yet for this study

Summary

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Conditions

  • Vascular Disease
  • CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Sponsors & Collaborators

  • Elisabethinen Hospital

    collaborator OTHER

  • Landeskrankenhaus Feldkirch

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Kathrin Eller, Univ.-Prof. · Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-15
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07170761 on ClinicalTrials.gov